Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_1
4
67%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

terminated233%
completed467%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults

NCT05148091
completed

Novel Mechanisms and Approaches to Treat Neonatal Sepsis

NCT02554630
terminated

Predictive Assay for Decision Making in Adjuvant Therapy

NCT05032352
completedphase_1

A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer

NCT03380871
completedphase_1

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

NCT02897765
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05148091Phase 1

The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults

Completed
NCT02554630

Novel Mechanisms and Approaches to Treat Neonatal Sepsis

Completed
NCT05032352

Predictive Assay for Decision Making in Adjuvant Therapy

Terminated
NCT03380871Phase 1

A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer

Completed
NCT02897765Phase 1

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Completed
NCT03597282Phase 1

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6